
Bin Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6097799/publications.pdf Version: 2024-02-01



RIN CHEN

#	Article	IF	CITATIONS
1	Methods to Measure the Inhibition of ABCG2 Transporter and Ferrochelatase Activity to Enhance Aminolevulinic Acid-Protoporphyrin IX Fluorescence-Guided Tumor Detection and Resection. Methods in Molecular Biology, 2022, 2394, 823-835.	0.9	1
2	Inhibition of ABCG2 transporter by lapatinib enhances 5-aminolevulinic acid-mediated protoporphyrin IX fluorescence and photodynamic therapy response in human glioma cell lines. Biochemical Pharmacology, 2022, 200, 115031.	4.4	12
3	Small molecule kinase inhibitors enhance aminolevulinic acid-mediated protoporphyrin IX fluorescence and PDT response in triple negative breast cancer cell lines. Journal of Biomedical Optics, 2021, 26, .	2.6	8
4	Therapeutic Enhancement of Verteporfinâ€mediated Photodynamic Therapy by mTOR Inhibitors. Photochemistry and Photobiology, 2020, 96, 358-364.	2.5	6
5	Evaluation of aminolevulinic acid-mediated protoporphyrin IX fluorescence and enhancement by ABCC2 inhibitors in renal cell carcinoma cells. Journal of Photochemistry and Photobiology B: Biology, 2020, 211, 112017.	3.8	12
6	Ferrochelatase Deficiency Abrogated the Enhancement of Aminolevulinic Acidâ€mediated Protoporphyrin <scp>IX</scp> by Iron Chelator Deferoxamine. Photochemistry and Photobiology, 2019, 95, 1052-1059.	2.5	18
7	Targeting Phosphatidylinositol 3-Kinase Signaling Pathway for Therapeutic Enhancement of Vascular-Targeted Photodynamic Therapy. Molecular Cancer Therapeutics, 2017, 16, 2422-2431.	4.1	30
8	Her2 oncogene transformation enhances 5-aminolevulinic acid-mediated protoporphyrin IX production and photodynamic therapy response. Oncotarget, 2016, 7, 57798-57810.	1.8	19
9	ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy. Scientific Reports, 2015, 5, 13298.	3.3	65
10	Effects of Silencing Heme Biosynthesis Enzymes on 5â€Aminolevulinic Acidâ€mediated Protoporphyrin <scp>IX</scp> Fluorescence and Photodynamic Therapy. Photochemistry and Photobiology, 2015, 91, 923-930.	2.5	35
11	Aminolevulinic Acid-Based Tumor Detection and Therapy: Molecular Mechanisms and Strategies for Enhancement. International Journal of Molecular Sciences, 2015, 16, 25865-25880.	4.1	131
12	Comparison between endothelial and tumor cells in the response to verteporfin-photodynamic therapy and a PI3K pathway inhibitor. Photodiagnosis and Photodynamic Therapy, 2015, 12, 19-26.	2.6	16
13	Therapeutic enhancement of vascular-targeted photodynamic therapy by inhibiting proteasomal function. Cancer Letters, 2013, 339, 128-134.	7.2	17
14	Combination of Phosphatidylinositol 3â€Kinases Pathway Inhibitor and Photodynamic Therapy in Endothelial and Tumor Cells. Photochemistry and Photobiology, 2012, 88, 1265-1272.	2.5	15
15	Intravital Microscopic Analysis of Vascular Perfusion and Macromolecule Extravasation after Photodynamic Vascular Targeting Therapy. Pharmaceutical Research, 2008, 25, 1873-1880.	3.5	36
16	Disparity between prostate tumor interior <i>versus</i> peripheral vasculature in response to verteporfinâ€mediated vascularâ€ŧargeting therapy. International Journal of Cancer, 2008, 123, 695-701.	5.1	49
17	Potentiation of Photodynamic Therapy with Hypericin by Mitomycin C in the Radiation-induced Fibrosarcoma-1 Mouse Tumor Model A¶. Photochemistry and Photobiology, 2007, 78, 278-282.	2.5	1
18	Pretreatment photosensitizer dosimetry reduces variation in tumor response. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1211-1220.	0.8	75

Bin Chen

#	Article	IF	CITATIONS
19	Protoporphyrin IX Level Correlates with Number of Mitochondria, But Increase in Production Correlates with Tumor Cell Size. Photochemistry and Photobiology, 2006, 82, 1334.	2.5	41
20	Tumor Vascular Permeabilization by Vascular-Targeting Photosensitization: Effects, Mechanism, and Therapeutic Implications. Clinical Cancer Research, 2006, 12, 917-923.	7.0	159
21	Vascular and Cellular Targeting for Photodynamic Therapy. Critical Reviews in Eukaryotic Gene Expression, 2006, 16, 279-306.	0.9	205
22	Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1216-1226.	0.8	112
23	Effect of tumor host microenvironment on photodynamic therapy in a rat prostate tumor model. Clinical Cancer Research, 2005, 11, 720-7.	7.0	48
24	Analysis of Effective Molecular Diffusion Rates for Verteporfin in Subcutaneous Versus Orthotopic Dunning Prostate Tumors [¶] . Photochemistry and Photobiology, 2004, 79, 323-331.	2.5	3
25	Blood Flow Dynamics after Photodynamic Therapy with Verteporfin in the RIF-1 Tumor. Radiation Research, 2003, 160, 452-459.	1.5	79
26	Antivascular Tumor Eradication by Hypericin-mediated Photodynamic Therapy¶. Photochemistry and Photobiology, 2002, 76, 509.	2.5	56